Jim Simons
ANTX icon

Jim Simons’s AN2 Therapeutics ANTX Stock Holding History

Jim Simons’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$680K Sell
198,800
-139,800
-41% -$289K ﹤0.01% 2462
2025
Q4 		$386K Sell
338,600
-46,997
-12% -$54.9K ﹤0.01% 2678
2025
Q3 		$490K Sell
385,597
-13,257
-3% -$15.2K ﹤0.01% 2805
2025
Q2 		$423K Buy
398,854
+30,146
+8% +$35.9K ﹤0.01% 2922
2025
Q1 		$501K Sell
368,708
-211,065
-36% -$266K ﹤0.01% 2742
2024
Q4 		$800K Buy
579,773
+155,973
+37% +$189K ﹤0.01% 2608
2024
Q3 		$453K Buy
423,800
+409,500
+2,864% +$711K ﹤0.01% 2833
2024
Q2 		$30.7K Buy
+14,300
New +$34K ﹤0.01% 3338
2022
Q4 		– Sell
-22,000
Closed -$382K – 4094
2022
Q3 		$382K Sell
22,000
-3,700
-14% -$43.1K ﹤0.01% 3076
2022
Q2 		$199K Buy
+25,700
New +$340K ﹤0.01% 3651

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jim Simons's ANTX Position: Q1 2026 in Review

Jim Simons reduced its AN2 Therapeutics (ANTX) stake by 41% in Q1 2026, selling an estimated $289K and leaving 198,800 shares worth $680K. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

Jim Simons first reported a position in ANTX in Q2 2022 and has held it in 10 quarters since. The position peaked at $800K in Q4 2024. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Jim Simons held 198,800 shares of AN2 Therapeutics worth $680K as of Q1 2026.
  • Jim Simons sold 139,800 AN2 Therapeutics shares in Q1 2026, an estimated $289K.
  • AN2 Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2462 holding.
  • Jim Simons first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • Jim Simons's AN2 Therapeutics position peaked at $800K in Q4 2024.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.